Evidence map›Paper›PMID 15209595›Full record

SynthesisJournal of general internal medicine2004

Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis.

Shelley R Salpeter, Judith M E Walsh, Elizabeth Greyber, Thomas M Ormiston, Edwin E Salpeter

Open access · greenAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Journal of general internal medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 8 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 8 syntheses or guidelines pooled it, 286 citations in OpenAlex.

  1. Pooled it
  2. Long-term hormone therapy for perimenopausal and postmenopausal women.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Effect of hormone therapy on tryptophan metabolism and atherosclerosis among postmenopausal women.Climacteric : the journal of the International Menopause Society · 2025
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Shelley R SalpeterDepartment of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA. salpeter@stanford.edu
Judith M E Walsh
Elizabeth Greyber
Thomas M Ormiston
Edwin E Salpeter
Santa Clara Valley Medical Center · USCornell University · USStanford Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess mortality associated with hormone replacement in younger and older postmenopausal women.

designA comprehensive search of MEDLINE, CINAHL, and EMBASE databases was performed to identify randomized controlled trials of hormone replacement therapy from 1966 to September 2002. The search was augmented by scanning selected journals through April 2003 and references of identified articles. Randomized trials of greater than 6 months' duration were included if they compared hormone replacement with placebo or no treatment, and reported at least 1 death. MEASUREMENTS: Outcomes measured were total deaths and deaths due to cardiovascular disease, cancer, or other causes. Odds ratios (OR) for total and cause-specific mortality were reported separately for trials with mean age of participants less than and greater than 60 years at baseline. MAIN

resultsPooled data from 30 trials with 26,708 participants showed that the OR for total mortality associated with hormone replacement was 0.98 (95% confidence interval [CI], 0.87 to 1.12). Hormone replacement reduced mortality in the younger age group (OR, 0.61; CI, 0.39 to 0.95), but not in the older age group (OR, 1.03; CI, 0.90 to 1.18). For all ages combined, treatment did not significantly affect the risk for cardiovascular or cancer mortality, but reduced mortality from other causes (OR, 0.67; CI, 0.51 to 0.88).

conclusionsHormone replacement therapy reduced total mortality in trials with mean age of participants under 60 years. No change in mortality was seen in trials with mean age over 60 years.

Indexed as

PostmenopauseAgedAge FactorsCardiovascular DiseasesCause of DeathFemaleHormone Replacement TherapyHumansMiddle AgedNeoplasmsRandomized Controlled Trials as Topic

Identifiers

PMID15209595
PMCPMC1492478
OpenAlexW2087034766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.